Diabetic nephropathy: landmark clinical trials and tribulations (Q38338539)

2 September 2017

1 reference

title

Diabetic nephropathy: landmark clinical trials and tribulations (English)

1 reference

2 September 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637638%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Gary C W Chan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637638%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

29 January 2015

1 reference

Nephrology Dialysis Transplantation

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637638%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637638%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637638%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

359-368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637638%20AND%20SRC:MED&resulttype=core&format=json

Global estimates of the prevalence of diabetes for 2010 and 2030

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Kidney disease and increased mortality risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Avosentan for overt diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Reversal of lesions of diabetic nephropathy after pancreas transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Standards of medical care in diabetes--2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Contraindications to the use of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Proteinuria: Is the ONTARGET renal substudy actually off target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

New therapies for diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

A pilot study of the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Pirfenidone is renoprotective in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Pirfenidone for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

SGLT inhibitors in management of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Urinary tract infections in patients with diabetes treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Endothelin: 20 years from discovery to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Effects of endothelin receptor antagonists on the progression of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Simultaneous pancreas-kidney transplantation and living related donor renal transplantation in patients with diabetes: is there a difference in survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

Sulodexide for Kidney Protection in Type 2 Diabetes Patients With Microalbuminuria: A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFU411

21 January 2018

Identifiers

DOI

10.1093/NDT/GFU411

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25637638%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference